Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Line item | Shotapharm | GM Pharmaceuticals | Aversi-Rational | Neoparmi | Bioparmi |
|---|---|---|---|---|---|
| Total Revenue | 327,423 | 184,906 | 63,771 | 19,189 | 10,150 |
| Total COGS | -164,945 | -62,907 | -36,548 | -12,616 | -4,625 |
| Gross Profit | 162,478 | 122,000 | 27,223 | 6,573 | 5,525 |
| Gross Margin | 49.6% | 66.0% | 42.7% | 34.3% | 54.4% |
| Total Operating Expenses | -5,564 | -59,937 | -15,856 | -6,950 | -6,373 |
| EBITDA | 156,914 | 62,063 | 11,367 | -376 | -847 |
| EBITDA Margin | 47.9% | 33.6% | 17.8% | -2.0% | -8.3% |
| Total D&A | 0 | -3,231 | 0 | -141 | -313 |
| EBIT / Operating Income | 156,914 | 54,377 | 11,367 | -517 | -1,161 |
| Profit Before Tax | 156,914 | 60,335 | 11,483 | -539 | -1,276 |
| Total Income Tax | 0 | 0 | -1,018 | -50 | 0 |
| Net Profit / (Loss) | 156,914 | 59,308 | 10,465 | -589 | -1,276 |
| Net Margin | 47.9% | 32.1% | 16.4% | -3.1% | -12.6% |
| Other Comprehensive Income | 7,060 | — | — | — | 2,385 |
| Total Comprehensive Income | 163,974 | — | — | — | 1,109 |
| Impairment (non-financial) | — | -4,455 | — | — | — |
| Total Interest Income | — | 3,320 | 82 | 21 | — |
| Total Interest Expense | — | -145 | -159 | -1 | — |
| Total Other Income | — | 2,783 | 193 | -41 | -115 |
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Shotapharm | Pharma | 47.9% | 95th pct | 110 |
| GM Pharmaceuticals | Pharma | 33.6% | 81st pct | 110 |
| Aversi-Rational | Pharma | 17.8% | 55th pct | 110 |
| Neoparmi | Pharma | -2.0% | 12th pct | 110 |
| Bioparmi | Pharma | -8.3% | 5th pct | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.